Clariane (FR:CLARI)
:CLARI
Top Page
Clariane
(CLARI)
Select Model
Select Model
Rating:47Neutral
Price Target:
€3.50
▼(-10.94% Downside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by balance-sheet risk (high and worsening leverage) and an extremely high P/E, despite supportive operating performance (revenue growth and positive free cash flow). Technical indicators are neutral and do not materially offset the fundamental risks.
Positive Factors
Accelerating Revenue Growth
Multi-year accelerating revenue and a ~16.5% YoY increase in 2025 indicate durable demand across long-term care, rehab, mental health and home-care segments. Sustained top-line growth supports better facility utilization, scale benefits, and reinvestment capacity over the next 2–6 months.
Negative Factors
High and Rising Leverage
Elevated and increasing leverage materially raises refinancing and interest-rate sensitivity. High debt limits capital allocation to strategic projects, increases default risk under earnings stress, and reduces resilience to funding-cost shocks, constraining medium-term strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Multi-year accelerating revenue and a ~16.5% YoY increase in 2025 indicate durable demand across long-term care, rehab, mental health and home-care segments. Sustained top-line growth supports better facility utilization, scale benefits, and reinvestment capacity over the next 2–6 months.
Read all positive factors
Clariane (CLARI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.32B
Dividend YieldN/A
Average Volume (3M)711.69K
Price to Earnings (P/E)873.3
Beta (1Y)1.61
Revenue Growth1.98%
EPS Growth85.87%
CountryFR
Employees61,798
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.17
Shares Outstanding356,754,460
10 Day Avg. Volume394,627
30 Day Avg. Volume711,689
Financial Highlights & Ratios
PEG Ratio-8.51
Price to Book (P/B)0.39
Price to Sales (P/S)0.26
P/FCF Ratio2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.10Price Target Upside-21.12% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)€5.49B
Clariane Business Overview & Revenue Model
Company Description
Clariane SE provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues. The company operates long-term care nursing homes, specialized clinics, and assisted living and s...
How the Company Makes Money
Clariane makes money primarily by providing healthcare and care services through its owned and operated facilities and home-care networks. Its revenue model is largely fee-for-service and occupancy/volume-driven: (1) Residential long-term care and...
Clariane Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
38
Negative
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.31B | 5.28B | 5.00B | 4.44B | 4.14B |
| Gross Profit | 431.50M | 4.84B | 1.57B | 4.09B | 3.83B |
| EBITDA | 1.01B | 1.01B | 952.04M | 907.45M | 946.76M |
| Net Income | 1.60M | -55.12M | -105.25M | 22.06M | 91.11M |
Balance Sheet | |||||
| Total Assets | 13.81B | 14.26B | 15.18B | 14.57B | 14.31B |
| Cash, Cash Equivalents and Short-Term Investments | 789.54M | 518.10M | 677.91M | 734.35M | 1.22B |
| Total Debt | 11.36B | 7.98B | 8.55B | 8.27B | 8.23B |
| Total Liabilities | 9.89B | 10.24B | 11.24B | 10.71B | 10.54B |
| Stockholders Equity | 3.61B | 3.69B | 3.58B | 3.54B | 3.49B |
Cash Flow | |||||
| Free Cash Flow | 577.76M | 600.10M | 320.04M | 116.36M | 311.05M |
| Operating Cash Flow | 796.46M | 908.13M | 804.15M | 681.66M | 839.97M |
| Investing Cash Flow | 137.55M | 47.69M | -669.52M | -770.26M | -825.28M |
| Financing Cash Flow | -670.90M | -1.11B | -193.61M | -550.13M | 31.38M |
Clariane Technical Analysis
Neutral
3.93
Price Trends
3.81
Negative
3.76
Negative
4.13
Negative
Market Momentum
-0.07
Negative
49.96
Neutral
80.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CLARI, the sentiment is Neutral. The current price of 3.93 is above the 20-day moving average (MA) of 3.67, above the 50-day MA of 3.81, and below the 200-day MA of 4.13, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 49.96 is Neutral, neither overbought nor oversold. The STOCH value of 80.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:CLARI.
Clariane Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €289.68M | 10.41 | 6.64% | 2.73% | 13.31% | -13.07% | |
60 Neutral | €1.13B | -7.25 | -4.36% | ― | 4.70% | -0.37% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €2.21B | -6.61 | -13.50% | ― | 6.30% | -100.37% | |
47 Neutral | €1.32B | 873.33 | -1.70% | ― | 1.98% | 85.87% |
* General Sector Average
FR:CLARI
Clariane
3.69
0.09
2.44%
FR:LNA
LNA Sante SA
27.80
7.03
33.85%
FR:EMEIS
Orpea SA
13.70
3.55
34.95%
FR:GDS
Ramsay Generale de Sante
10.25
0.63
6.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.